Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oral cavity bacteria comprise a highly complex, site-specific community of microorganisms inhabiting the human mouth, with over 700 described species spanning at least 12 bacterial phyla, such as Firmicutes, Proteobacteria, Actinobacteria, Bacteroidetes, and Fusobacteria[1][3][5]. These bacteria exist in symbiotic equilibrium, contributing to oral and general health, but shifts in composition (dysbiosis) can trigger oral and systemic diseases, including dental caries, periodontitis, and links to cardiovascular and metabolic disorders. Intervention strategies are shifting toward selective targeting of pathogenic bacteria or restoration of healthy communities through probiotics or microbiota transplantation, rather than broad-spectrum microbial eradication[2][4][6].
Broad-spectrum antimicrobial action (disrupting or killing diverse oral bacteria) Targeted eradication of dysbiotic/pathogenic bacteria (e.g., inhibition of glucan synthesis in *S. mutans*) Probiotic colonization and competitive exclusion of pathogens Biofilm modulation Immunomodulation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oral cavity bacterium.